| Autor: |
Renata Moll-Bernardes, Andrea Silvestre de Sousa, Ariane V. S. Macedo, Renato D. Lopes, Narendra Vera, Luciana C. R. Maia, André Feldman, Guilherme D. A. S. Arruda, Mauro J. C. Castro, Pedro M. Pimentel-Coelho, Denílson C. de Albuquerque, Thiago Ceccatto de Paula, Thyago A. B. Furquim, Vitor A. Loures, Karla G. D. Giusti, Nathália M. de Oliveira, Fábio A. De Luca, Marisol D. M. Kotsugai, Rafael A. M. Domiciano, Mayara Fraga Santos, Olga Ferreira de Souza, Fernando A. Bozza, Ronir Raggio Luiz, Emiliano Medei |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Frontiers in Cardiovascular Medicine, Vol 8 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2297-055X |
| DOI: |
10.3389/fcvm.2021.702507 |
| Popis: |
Background: Cardiovascular comorbidities such as hypertension and inflammatory response dysregulation are associated with worse COVID-19 prognoses. Different cytokines have been proposed to play vital pathophysiological roles in COVID-19 progression, but appropriate prognostic biomarkers remain lacking. We hypothesized that the combination of immunological and clinical variables at admission could predict the clinical progression of COVID-19 in hypertensive patients.Methods: The levels of biomarkers, including C-reactive protein, lymphocytes, monocytes, and a panel of 29 cytokines, were measured in blood samples from 167 hypertensive patients included in the BRACE-CORONA trial. The primary outcome was the highest score during hospitalization on the modified WHO Ordinal Scale for Clinical Improvement. The probability of progression to severe disease was estimated using a logistic regression model that included clinical variables and biomarkers associated significantly with the primary outcome.Results: During hospitalization, 13 (7.8%) patients showed progression to more severe forms of COVID-19, including three deaths. Obesity, diabetes, oxygen saturation, lung involvement on computed tomography examination, the C-reactive protein level, levels of 15 cytokines, and lymphopenia on admission were associated with progression to severe COVID-19. Elevated levels of interleukin-10 and interleukin-12 (p70) combined with two or three of the abovementioned clinical comorbidities were associated strongly with progression to severe COVID-19. The risk of progression to severe disease reached 97.5% in the presence of the five variables included in our model.Conclusions: This study demonstrated that interleukin-10 and interleukin-12 (p70) levels, in combination with clinical variables, at hospital admission are key biomarkers associated with an increased risk of disease progression in hypertensive patients with COVID-19. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
